Simbrinza Dosage
Generic name: Brinzolamide 10mg in 1mL, Brimonidine Tartrate 2mg in 1mL
Dosage form: ophthalmic suspension
Drug class: Ophthalmic glaucoma agents
Medically reviewed by Drugs.com. Last updated on Mar 11, 2025.
The recommended dose is one drop of SIMBRINZA in the affected eye(s) three times daily. Shake well before use. SIMBRINZA ophthalmic suspension may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
More about Simbrinza (brimonidine / brinzolamide ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (28)
- Side effects
- During pregnancy
- FDA approval history
- Drug class: ophthalmic glaucoma agents
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Xalatan
Xalatan (latanoprost) is used to treat certain types of glaucoma. Includes Xalatan side effects ...
Lumigan
Lumigan is used to treat open angle glaucoma. Learn about side effects, interactions and indications.
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Cosopt
Cosopt reduces the amount of fluid in the eye and is used to treat glaucoma. Learn about side ...
Combigan
Combigan (brimonidine and timolol) is used to treat glaucoma or ocular hypertension. Includes ...
Alphagan P
Alphagan P is used to treat glaucoma or ocular hypertension (high pressure inside the eye). Learn ...
Bimatoprost ophthalmic
Bimatoprost ophthalmic is used for glaucoma, open angle, intraocular hypertension
Dorzolamide ophthalmic
Dorzolamide ophthalmic is used for glaucoma, open angle, intraocular hypertension
Brimonidine ophthalmic
Brimonidine ophthalmic is used for eye redness, glaucoma, open angle, intraocular hypertension
Timolol ophthalmic
Timolol ophthalmic is used for glaucoma, open angle, intraocular hypertension
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
